PMID- 33162540
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 61
IP  - 9
DP  - 2020
TI  - [Allogeneic hematopoietic stem cell transplantation for patients with aplastic 
      anemia].
PG  - 1388-1394
LID - 10.11406/rinketsu.61.1388 [doi]
AB  - Allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte 
      antigen (HLA)-matched related donor is an effective treatment option for sever 
      aplastic anemia (SAA). HSCT from an unrelated donor has also been reported. 
      Engraftment failure and graft-versus-host disease (GVHD) are major obstacles in 
      HSCT for SAA, and the combination of high-dose cyclophosphamide (CY) and 
      anti-thymocyte globulin (ATG) has been utilized as a conditioning regimen for 
      overcoming these obstacles. However, cardiac toxicity due to high-dose CY has 
      been a major challenge, and the reduction of CY with the addition of fludarabine 
      (Flu) has recently been considered to decrease toxicity. In Kanto Study Group for 
      Cell Therapy (KSGCT), a prospective study using Flu, reduced-dose CY, and 
      low-dose thymoglobulin as a conditioning regimen was performed, which 
      demonstrated a promising result with the overall survival rate of 96.3% at one 
      year. However, it should be noted that the use of Flu may affect the occurrence 
      of secondary graft failure. Outcomes in HSCT from alternative donors, including 
      cord blood and haploidentical-related donors, are improving. Therefore, we have 
      more options in HSCT for SAA.
FAU - Kako, Shinichi
AU  - Kako S
AD  - Division of Hematology, Jichi Medical University Saitama Medical Center.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
SB  - IM
MH  - *Anemia, Aplastic/therapy
MH  - *Graft vs Host Disease
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Prospective Studies
MH  - Transplantation Conditioning
OTO - NOTNLM
OT  - Allogeneic hematopoietic stem cell transplantation
OT  - Aplastic anemia
OT  - Cyclophosphamide
OT  - Thymoglobulin
EDAT- 2020/11/10 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/11/09 05:29
PHST- 2020/11/09 05:29 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.11406/rinketsu.61.1388 [doi]
PST - ppublish
SO  - Rinsho Ketsueki. 2020;61(9):1388-1394. doi: 10.11406/rinketsu.61.1388.